By vgreene, 28 October, 2021 Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID 19 A Randomized Clinical Trial ORCHID
By vgreene, 28 October, 2021 No significant difference in clinical status at day 15 w HCQ vs SOC alone OR 1 21 95 CI 0 69 to 2 11 or HCQ AZ vs SOC alone OR 0 99 95 CI 0 57 to 1 73 no significant difference in secondary outcomes such as intubation w in 15 days O2 requirement LOS QT pr
By vgreene, 28 October, 2021 Multicenter open label RCT 667 hospitalized pts mean age 50y w mild mod COVID 19 58 pts required no O2 and
By vgreene, 28 October, 2021 Study considerations randomized but open label pts had mild mod dz primary outcome assessment changed mid study to be more granular observer bias
By vgreene, 28 October, 2021 KEY FINDINGS HCQ or HCQ AZ did not improve clinical status at 15 days vs SOC
By vgreene, 28 October, 2021 Hydroxychloroquine With or Without Azithromycin in Mild to Moderate Covid 19
By vgreene, 28 October, 2021 Primary composite endpoint intubation or death rates higher w HCQ 32 vs no HCQ 15 in unadjusted analysis HR 2 37 95 CI 1 84 to 3 02 adjusted analysis showed no significant association btwn HCQ use and composite endpoint HR 1 04 95 CI 0 82 to 1 32
By vgreene, 28 October, 2021 Observational cohort study w propensity score matching 1 376 consecutive hospitalized pts 60 pts 60y w confirmed mod severe COVID 19 811 pts treated w HCQ 600 mg bid x2 then 400 mg daily x4 days 565 pts did not receive HCQ 45 pts also treated w AZ 500 mg
